British drugmaker AstraZeneca Plc said Ironwood Pharmaceuticals Inc would buy the US marketing rights for its newly-approved gout drug for up to $265 million.
The deal would give Ironwood the rights to sell the drug, Zurampic, which was approved in the United States last year to treat high levels of uric acid in the blood of patients suffering from gout.

AstraZeneca did not mention any upfront payment to be made by the U.S. drugmaker in its statement on Tuesday.

- (Reuters)

This article was corrected on Friday, May 6th